Person: Karimah Es Sabar

Mark Lievonen

Mark Lievonen, president of Sanofi Pasteur Ltd, has been appointed chair of the board of directors for Canada’s Research-Based Pharmaceutical Companies (Rx&D) for 2013-14. Lievonen joined Sanofi Pasteur in 1983 and held a number of senior positions before being named president in 1999. Lievonen holds a BBA in accounting and an MBA from the Schulich…

Sean Cunliffe

Sean Cunliffe has been appointed CEO of Sitka Biopharma Inc, a spinoff of CDRD Ventures Inc (see brief on this page). Cunliffe is a pharmaceutical sales and marketing executive with more than 30 years of experience working in big pharma. At Sitka he will work with founding scientists Dr Helen Burt and Dr Don Brooks…

Dr David Lizius

Dr David Lizius has been appointed president and CEO of COM DEV Canada, the Ottawa-based division of COM DEV International Ltd, Cambridge ON. Lizius replaces George Cwynar, a veteran high-tech executive and former CEO of Mosaid Technologies who left abruptly after 18 months at COM DEV to “pursue other opportunities”. Lizius has 30 years of…

Karimah Es Sabar

Karimah Es Sabar has been appointed senior VP business and strategic affairs with the Centre for Drug Research and Development (CDRD) as the Vancouver-based organization expands activities across Canada and internationally. Es Sabar is currently president of Life Sciences BC and will take on joint responsibilities with both organizations until April/10 when she assumes CDRD…

Howard Gwin

Howard Gwin has joined Bridge-scale Partners as a venture partner operating out of the Menlo Park CA-based investment firm’s Toronto offices. Gwin is a veteran of the software and services sectors and sits on the board of several Canadian software companies. Prior to joining Bridgescale, he was president of Solect Technology Group and held executive…

Karimah Es Sabar

Karimah Es Sabar has been appointed executive director of BC Biotech, an association representing the province’s biotechnology industry. Es Sabar was most recently VP and COO of Medsurge Medical Inc. Prior to that, she was founder and managing director of SAL Healthcare Ltd, a marketing, distribution and consulting firm in Nairobi Kenya. Es Sabar holds…

Dr André Musy

Dr André Musy has been appointed DG of Ouranos, the research institute of Hydro-Québec. Musy comes to Ouranos from the École Polytechnique Fédérale de Lausanne (EPFL). His experience in hydrology, the environment and land and water use is well suited to Ouranos’ two-pronged research program of climate science/hydrology and impacts and adaptation strategies. Musy holds…

Dr Trevor Hawkins

Dr Trevor Hawkins has been appointed to the newly created position of chief science and technology officer at MDS Inc. Hawkins joins MDS during a period of transition in the executive suite (see below). He was previously president of the molecular diagnostics business unit at GE Healthcare and senior VP development and new business initiatives…

Stephen DeFalco

Stephen DeFalco has been appointed COO of MDS Inc and will become president and CEO when he replaces retiring John Rogers at the end of 2005. Defalco is chair and CEO of US Genomics, a firm he founded in 2003. Prior to that he was president of PerkinElmer Instruments and senior VP of PerkinElmer Inc.…

Gregory McKee

Gregory McKee has been appointed president and CEO of Victoria-based Stressgen Biotechnologies Corp, replacing Dan Korpolinski. The move comes after Stressgen withdrew its preliminary prospectus for a common share offering and a decision to sell its bioreagents business to a US firm (see New Briefs). Prior to his appointment, McKee was Stressgen’s chief financial officer…